Ebola Treatments Would Qualify For FDA Priority Review Under Bill Passed By Senate Committee

The Hill: Senate panel passes measure to speed up approval of Ebola drugs
“The Senate Health, Education, Labor and Pensions (HELP) Committee approved a measure Wednesday designed to speed the approval of Ebola drugs. The bill (S 2917) would make Ebola treatments eligible for priority review vouchers at the Food and Drug Administration (FDA), cutting down on the evaluation time taken by regulators…” (Viebeck, 11/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.